Cargando…

Epidemiology of invasive meningococcal disease in Canada, 2012–2019

BACKGROUND: A variety of routine childhood and adolescent meningococcal vaccination programs using monovalent (serogroup C) and quadrivalent (A, C, Y, W) conjugate vaccines have been implemented in Canada since 2002, resulting in a decrease in invasive meningococcal disease (IMD) incidence, particul...

Descripción completa

Detalles Bibliográficos
Autores principales: Saboui, Myriam, Tsang, Raymond SW, MacTavish, Robert, Agarwal, Amisha, Li, Y Anita, Salvadori, Marina I, Squires, Susan G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Health Agency of Canada 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263176/
https://www.ncbi.nlm.nih.gov/pubmed/37325257
http://dx.doi.org/10.14745/ccdr.v48i05a06
_version_ 1785058193805672448
author Saboui, Myriam
Tsang, Raymond SW
MacTavish, Robert
Agarwal, Amisha
Li, Y Anita
Salvadori, Marina I
Squires, Susan G
author_facet Saboui, Myriam
Tsang, Raymond SW
MacTavish, Robert
Agarwal, Amisha
Li, Y Anita
Salvadori, Marina I
Squires, Susan G
author_sort Saboui, Myriam
collection PubMed
description BACKGROUND: A variety of routine childhood and adolescent meningococcal vaccination programs using monovalent (serogroup C) and quadrivalent (A, C, Y, W) conjugate vaccines have been implemented in Canada since 2002, resulting in a decrease in invasive meningococcal disease (IMD) incidence, particularly in serogroup C. Meningococcal vaccines have also been used for outbreak response, including the multicomponent vaccine serogroup B vaccine. This report describes the epidemiology of IMD in Canada from 2012 to 2019. METHODS: Case data were obtained from the National Enhanced IMD Surveillance System between January 1, 2012 and December 31, 2019. Isolates were sent to the National Microbiology Laboratory for confirmation of serogroup and further studies including phenotype and clonal complex identification. RESULTS: A total of 983 cases of IMD were reported between 2012 and 2019. Overall, the age-adjusted incidence of IMD from 2012 to 2019 was 0.34 cases per 100,000 population per year when standardized to the Canadian 2011 population age distribution (95% CI: 0.32–0.36). Infants younger than one year of age had the highest average age-specific incidence rate (3.6 cases per 100,000 population per year, 95% CI: 2.8–4.3). The highest age-adjusted incidence rate was associated with serogroup B (0.17 cases per 100, 000 population per year, 95% CI: 0.16–0.19). Prior to 2015, most invasive serogroup W isolates were identified as clonal complex 22 (ST-22 CC) and the increase in serogroup W in Canada in recent years has been associated with the replacement of the endemic ST-22 CC with the hyper-virulent ST-11 CC. CONCLUSION: Invasive meningococcal disease is a rare but severe infection in Canada that mostly affects the very young. Serogroup B continues to account for the greatest proportion of disease. Serogroup W associated with ST-11 CC is becoming a growing contributor of disease in all age groups not protected by serogroup W-containing vaccines.
format Online
Article
Text
id pubmed-10263176
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Health Agency of Canada
record_format MEDLINE/PubMed
spelling pubmed-102631762023-06-15 Epidemiology of invasive meningococcal disease in Canada, 2012–2019 Saboui, Myriam Tsang, Raymond SW MacTavish, Robert Agarwal, Amisha Li, Y Anita Salvadori, Marina I Squires, Susan G Can Commun Dis Rep Epidemiologic Study BACKGROUND: A variety of routine childhood and adolescent meningococcal vaccination programs using monovalent (serogroup C) and quadrivalent (A, C, Y, W) conjugate vaccines have been implemented in Canada since 2002, resulting in a decrease in invasive meningococcal disease (IMD) incidence, particularly in serogroup C. Meningococcal vaccines have also been used for outbreak response, including the multicomponent vaccine serogroup B vaccine. This report describes the epidemiology of IMD in Canada from 2012 to 2019. METHODS: Case data were obtained from the National Enhanced IMD Surveillance System between January 1, 2012 and December 31, 2019. Isolates were sent to the National Microbiology Laboratory for confirmation of serogroup and further studies including phenotype and clonal complex identification. RESULTS: A total of 983 cases of IMD were reported between 2012 and 2019. Overall, the age-adjusted incidence of IMD from 2012 to 2019 was 0.34 cases per 100,000 population per year when standardized to the Canadian 2011 population age distribution (95% CI: 0.32–0.36). Infants younger than one year of age had the highest average age-specific incidence rate (3.6 cases per 100,000 population per year, 95% CI: 2.8–4.3). The highest age-adjusted incidence rate was associated with serogroup B (0.17 cases per 100, 000 population per year, 95% CI: 0.16–0.19). Prior to 2015, most invasive serogroup W isolates were identified as clonal complex 22 (ST-22 CC) and the increase in serogroup W in Canada in recent years has been associated with the replacement of the endemic ST-22 CC with the hyper-virulent ST-11 CC. CONCLUSION: Invasive meningococcal disease is a rare but severe infection in Canada that mostly affects the very young. Serogroup B continues to account for the greatest proportion of disease. Serogroup W associated with ST-11 CC is becoming a growing contributor of disease in all age groups not protected by serogroup W-containing vaccines. Public Health Agency of Canada 2022-05-05 /pmc/articles/PMC10263176/ /pubmed/37325257 http://dx.doi.org/10.14745/ccdr.v48i05a06 Text en Public Health Agency of Canada, 2022 https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY) 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Epidemiologic Study
Saboui, Myriam
Tsang, Raymond SW
MacTavish, Robert
Agarwal, Amisha
Li, Y Anita
Salvadori, Marina I
Squires, Susan G
Epidemiology of invasive meningococcal disease in Canada, 2012–2019
title Epidemiology of invasive meningococcal disease in Canada, 2012–2019
title_full Epidemiology of invasive meningococcal disease in Canada, 2012–2019
title_fullStr Epidemiology of invasive meningococcal disease in Canada, 2012–2019
title_full_unstemmed Epidemiology of invasive meningococcal disease in Canada, 2012–2019
title_short Epidemiology of invasive meningococcal disease in Canada, 2012–2019
title_sort epidemiology of invasive meningococcal disease in canada, 2012–2019
topic Epidemiologic Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263176/
https://www.ncbi.nlm.nih.gov/pubmed/37325257
http://dx.doi.org/10.14745/ccdr.v48i05a06
work_keys_str_mv AT sabouimyriam epidemiologyofinvasivemeningococcaldiseaseincanada20122019
AT tsangraymondsw epidemiologyofinvasivemeningococcaldiseaseincanada20122019
AT mactavishrobert epidemiologyofinvasivemeningococcaldiseaseincanada20122019
AT agarwalamisha epidemiologyofinvasivemeningococcaldiseaseincanada20122019
AT liyanita epidemiologyofinvasivemeningococcaldiseaseincanada20122019
AT salvadorimarinai epidemiologyofinvasivemeningococcaldiseaseincanada20122019
AT squiressusang epidemiologyofinvasivemeningococcaldiseaseincanada20122019